Treatment of restless legs syndrome with gabapentin

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Gabapentin is a well tolerated anticonvulsant, structurally related to γ-aminobutyric acid, with an unknown mechanism of action. Restless legs syndrome (RLS) is a disorder characterized by sensory and motor symptoms in the legs that is best treated with dopaminergic drugs and opiates. In this open-label study, eight patients with RLS were treated with gabapentin. Four of the eight had a beneficial response, three with almost complete resolution of symptoms for up to 6 months. For a disorder that is often difficult to treat, these results are encouraging, and they suggest that a placebo- controlled trial is warranted.

Original languageEnglish (US)
Pages (from-to)148-151
Number of pages4
JournalClinical Neuropharmacology
Volume20
Issue number2
StatePublished - 1997

Fingerprint

Restless Legs Syndrome
Opiate Alkaloids
Sensation Disorders
Aminobutyrates
Dopamine Agents
Anticonvulsants
Leg
Placebos
Therapeutics
gabapentin
Motor Disorders

Keywords

  • Gabapentin
  • Movement disorders
  • Restless legs syndrome

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Treatment of restless legs syndrome with gabapentin. / Adler, Charles Howard.

In: Clinical Neuropharmacology, Vol. 20, No. 2, 1997, p. 148-151.

Research output: Contribution to journalArticle

@article{ca45bb39c1574c08abf8f05fe8250906,
title = "Treatment of restless legs syndrome with gabapentin",
abstract = "Gabapentin is a well tolerated anticonvulsant, structurally related to γ-aminobutyric acid, with an unknown mechanism of action. Restless legs syndrome (RLS) is a disorder characterized by sensory and motor symptoms in the legs that is best treated with dopaminergic drugs and opiates. In this open-label study, eight patients with RLS were treated with gabapentin. Four of the eight had a beneficial response, three with almost complete resolution of symptoms for up to 6 months. For a disorder that is often difficult to treat, these results are encouraging, and they suggest that a placebo- controlled trial is warranted.",
keywords = "Gabapentin, Movement disorders, Restless legs syndrome",
author = "Adler, {Charles Howard}",
year = "1997",
language = "English (US)",
volume = "20",
pages = "148--151",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Treatment of restless legs syndrome with gabapentin

AU - Adler, Charles Howard

PY - 1997

Y1 - 1997

N2 - Gabapentin is a well tolerated anticonvulsant, structurally related to γ-aminobutyric acid, with an unknown mechanism of action. Restless legs syndrome (RLS) is a disorder characterized by sensory and motor symptoms in the legs that is best treated with dopaminergic drugs and opiates. In this open-label study, eight patients with RLS were treated with gabapentin. Four of the eight had a beneficial response, three with almost complete resolution of symptoms for up to 6 months. For a disorder that is often difficult to treat, these results are encouraging, and they suggest that a placebo- controlled trial is warranted.

AB - Gabapentin is a well tolerated anticonvulsant, structurally related to γ-aminobutyric acid, with an unknown mechanism of action. Restless legs syndrome (RLS) is a disorder characterized by sensory and motor symptoms in the legs that is best treated with dopaminergic drugs and opiates. In this open-label study, eight patients with RLS were treated with gabapentin. Four of the eight had a beneficial response, three with almost complete resolution of symptoms for up to 6 months. For a disorder that is often difficult to treat, these results are encouraging, and they suggest that a placebo- controlled trial is warranted.

KW - Gabapentin

KW - Movement disorders

KW - Restless legs syndrome

UR - http://www.scopus.com/inward/record.url?scp=0030898703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030898703&partnerID=8YFLogxK

M3 - Article

C2 - 9099467

AN - SCOPUS:0030898703

VL - 20

SP - 148

EP - 151

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 2

ER -